本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Ventyx Biosciences, Inc.

3.56
-0.3000-7.77%
盘后3.50-0.0600-1.69%18:55 EDT
成交量:147.40万
成交额:533.27万
市值:2.54亿
市盈率:-2.12
高:3.88
开:3.86
低:3.48
收:3.86
52周最高:4.05
52周最低:0.7830
股本:7,130.85万
流通股本:5,355.59万
量比:0.89
换手率:2.75%
股息:- -
股息率:- -
每股收益(TTM):-1.6773
每股收益(LYR):-1.9732
净资产收益率:-48.56%
总资产收益率:-30.23%
市净率:1.21
市盈率(LYR):-1.80

数据加载中...

2023/05/31

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/11

重要事件披露

8-K - Current report
2023/05/11

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/05/05

关联方拟减持公告

144 - Report of proposed sale of securities
2023/05/03

关联方拟减持公告

144 - Report of proposed sale of securities
2023/05/03

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/28

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/07

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/23

重要事件披露

8-K - Current report
2023/03/23

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/03/22

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/02

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/14

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/01/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/01/26

重要事件披露

8-K - Current report
2023/01/12

重要事件披露

8-K - Current report
2023/01/05

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/12/30

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/12/20

重要事件披露

8-K - Current report